Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application

Stock News

Sep 10

Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.

Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.

This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1185698776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185698776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185698776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185698776","market":"sg","top_or_hot":-1,"title":"Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application","media":"Stock News","content":"<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-10 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1185698776","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185698776","pubTimestamp":1789040057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","BK0028":"国家队","BK0239":"医药制造","000931":"中关村","BK0178":"特色小镇","BK0075":"新三板"},"translate_title":"北京盛捷科技替格瑞洛片上市申请获国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1,"IPOS":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}